Danavorexton

From WikiMD's Wellness Encyclopedia

Error creating thumbnail:
Danavorexton Structure

Danavorexton is a pharmaceutical drug that acts as an orexin receptor antagonist. It is primarily used in the treatment of sleep disorders, particularly narcolepsy. Danavorexton works by blocking the action of orexin, a neuropeptide that regulates arousal, wakefulness, and appetite.

Mechanism of Action[edit | edit source]

Danavorexton functions by inhibiting the binding of orexin to its receptors, specifically orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Orexin, also known as hypocretin, is produced in the hypothalamus and plays a crucial role in maintaining wakefulness and regulating the sleep-wake cycle. By blocking orexin receptors, Danavorexton reduces the stimulatory effects of orexin, thereby promoting sleep.

Clinical Uses[edit | edit source]

Danavorexton is primarily indicated for the treatment of narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden episodes of muscle weakness (cataplexy). It may also be used off-label for other sleep disorders, such as insomnia and sleep apnea, although its efficacy and safety for these conditions are still under investigation.

Side Effects[edit | edit source]

Common side effects of Danavorexton include:

Serious side effects are rare but may include:

Contraindications[edit | edit source]

Danavorexton is contraindicated in individuals with a history of severe allergic reactions to the drug or any of its components. It should be used with caution in patients with a history of depression or other psychiatric disorders.

Pharmacokinetics[edit | edit source]

Danavorexton is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the urine. The drug has a half-life of approximately 12 hours, allowing for once-daily dosing.

Research and Development[edit | edit source]

Danavorexton is currently undergoing clinical trials to evaluate its efficacy and safety in a broader range of sleep disorders. Preliminary results suggest that it may be a promising treatment option for patients who do not respond to traditional therapies.

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]

-


Contributors: Prab R. Tumpati, MD